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Recent evidence suggests that many signaling mole-
cules localize in microdomains of the plasma membrane,
particularly caveolae. In this study, overexpression of
adenylyl cyclase was used as a functional probe of G
protein-coupled receptor (GPCR) compartmentation.
We found that three endogenous receptors in neonatal
rat cardiomyocytes couple with different levels of effi-
ciency to the activation of adenylyl cyclase type 6 (AC6),
which localizes to caveolin-rich membrane fractions.
Overexpression of AC6 enhanced the maximal cAMP re-
sponse to 1-adrenergic receptor (1AR)-selective acti-
vation 3.7-fold, to 2AR-selective activation only 1.6-fold
and to prostaglandin E2 (PGE2) not at all. Therefore, the
rank order of efficacy in coupling to AC6 is 1AR >
2AR > prostaglandin E2 receptor (EP2R). 2AR cou-
pling efficiency was greater when we overexpressed the
receptor or blocked its desensitization by expressing
ARKct, an inhibitor of G protein-coupled receptor ki-
nase activation, but was not significantly greater when
cells were treated with pertussis toxin. Assessment of
receptor and AC expression indicated co-localization of
AC5/6, 1AR, and 2AR, but not EP2R, in caveolin-rich
membranes and caveolin-3 immunoprecipitates, likely
explaining the observed activation of AC6 by AR sub-
types but lack thereof by PGE2. When cardiomyocytes
were stimulated with a AR agonist, 2AR were no lon-
ger found in caveolin-3 immunoprecipitates; an effect
that was blocked by expression of ARKct. Thus, ago-
nist-induced translocation of 2AR out of caveolae
causes a sequestration of receptor from effector and
likely contributes to the lower efficacy of 2AR coupling
to AC6 as compared with 1AR, which do not similarly
translocate. Therefore, spatial co-localization is a key
determinant of efficiency of coupling by particular ex-
tracellular signals to activation of GPCR-linked
effectors.
Regulation of cells by G protein-coupled receptors (GPCRs)1
involves the sequential flow of information from the receptors
via heterotrimeric G proteins to effector molecules. Among the
GPCRs, probably the most well studied are the -adrenergic
receptors (AR), which are widely expressed in cells through-
out the body, including cardiac myocytes. Cardiac AR, which
are activated by neuronally released and circulating cat-
echolamines, change several aspects of cardiac function, includ-
ing increases in the rate and force of contraction and the rate of
relaxation. AR exerts the majority of its effects by coupling to
the heterotrimeric G protein, Gs, and the stimulation of adeny-
lyl cyclase (AC) activity. Activity of AC produces the second
messenger cAMP, which, via activation of protein kinase A,
alters intracellular Ca2 dynamics and contractile function by
phosphorylating calcium channels, troponin I, and phospho-
lamban (1, 2). The 1AR is the predominant subtype in cardiac
myocytes, outnumbering 2AR by 4:1 (3, 4). However, inter-
est has grown recently in the possibility that these receptor
subtypes are not redundant, but differentially regulate cardiac
function. The distinct physiological actions of 1AR and 2AR
may represent coupling to different signaling pathways (5–8)
and/or different spatial localization within the heart or within
single cells (9, 10).
Expression of both AR and AC in distinct caveolar microdo-
mains of the plasma membrane has been recently demon-
strated in both non-cardiac and cardiac cells (10–14). Caveolae,
detectable as plasma membrane invaginations, are enriched in
the protein caveolin and in sphingolipid and cholesterol,
thereby representing a distinct protein and lipid environment,
which appears to attract and retain a subset of plasma mem-
brane proteins (15, 16). Compartmentation of AR and AC (and
portions of cellular Gs) challenges the concept that components
of GPCR signal transduction are randomly distributed protein
entities that interact via diffusion over long distances in the
plasma membrane. Instead, the sparsely expressed signaling
proteins may be restricted to such plasmalemmal microdo-
mains to facilitate rapid and specific signal transduction (17,
18) and regulation by co-localized molecules (19).
We previously reported that overexpression of AC6 in neo-
natal rat cardiac myocytes selectively enhances responses to
AR activation but not to activation of prostanoid, adenosine,
glucagon, or histamine receptors and found that AC6 and 1AR
are co-localized in caveolar membranes of cardiomyocytes (13).
The goal of the present study was to test the role of receptor-
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effector co-localization in caveolae as a contributor to the abil-
ity of different GPCRs to regulate second messenger genera-
tion. We used AC6 overexpression as a read-out of receptor
coupling by comparing the degree to which it enhanced maxi-
mal cAMP response to receptor activation. We show here that
1AR couple more efficaciously to AC6 as compared with 2AR,
but that increasing total expression of 2AR or blocking their
desensitization and translocation out of caveolae enhances the
coupling of this receptor to AC6. Taken together with the fact
that prostanoid receptors, which do not couple to AC6, were not
found in caveolae, we conclude that GPCR ability to couple to
the stimulation of AC6 depends upon the co-localization of
sufficient active receptors in caveolin-rich membrane microdo-
mains, the predominant subcellular site of AC6 expression.
EXPERIMENTAL PROCEDURES
Materials—Adenovirus-expressing murine AC6 was generated as
described previously (20). ARKct adenovirus was a gift from Robert
Lefkowitz (Duke University). Primary antibodies for 1AR, 2AR, and
AC5/6 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Primary antibody for caveolin-3 was obtained from BD PharMingen.
Radiolabeled chemicals were obtained from PerkinElmer Life Sciences.
All other chemicals and reagents were obtained from Sigma Chemical.
Measurement of Adenylyl Cyclase Activity—Neonatal cardiac myo-
cytes were prepared and maintained as described previously (13, 20).
Cells were infected 2 days after plating with indicated adenoviral con-
struct(s) for 20 h (10–100 MOI/cell). Control cells were treated with an
identical adenoviral construct containing the lacZ gene. After infection,
cells were washed extensively and allowed to equilibrate for 24 h.
Membranes were prepared by rinsing cells twice in ice-cold PBS then
scraping cells into hypotonic homogenizing buffer (30 mM NaHEPES, 5
mM MgCl2, 1 mM EGTA, 2 mM dithiothreitol, pH 7.5) and homogenizing
with 20 strokes in a Dounce homogenizer. Homogenate was spun at
300  g for 5 min at 4 °C. Supernatant was then transferred to a clean
centrifuge tube and spun at 5,000  g for 10 min. The pellet was
suspended in membrane buffer (30 mM NaHEPES, 5 mM MgCl2, 2 mM
dithiothreitol, pH 7.5) to attain 1 mg/ml total protein concentration.
In other studies, AC activity was measured in caveolin-3 immunopre-
cipitates. Cells were scraped and homogenized in a modified lysis buffer
with a lower concentration of detergent (50 mM Tris-HCl, pH 7.5, 150
mM NaCl, 5 mM MgCl2, 1 mM EGTA, 2 mM dithiothreitol, 0.5% Igepal
CA-630, plus mammalian protease inhibitor mixture). Homogenate was
precleared with 50 l of protein A-agarose for 30 min at 4 °C then
incubated with caveolin-3 monoclonal antibody (BD PharMingen) for
1 h. Antibody complexes were then precipitated following incubation
with protein A-agarose and resuspended in membrane buffer. The
assay was conducted by adding 30 l of sample (membranes or immu-
noprecipitate) into tubes containing assay buffer (30 mM NaHEPES,
100 mM NaCl, 1 mM EGTA, 10 mM MgCl2, 1 mM isobutylmethylxan-
thine, 1 mM ATP, 10 mM phosphocreatine, 5 M GTP, 60 units/ml
creatine phosphokinase, and 0.1% bovine serum albumin, pH 7.5.) and
drugs of interest. The mixture was incubated for 15 min at 30 °C, and
reactions were stopped by boiling for 5 min. cAMP content of each tube
was assayed for cAMP content by radioimmunoassay as described pre-
viously (13). Total protein concentration was determined using a dye-
binding protein assay (Bio-Rad).
Measurement of cAMP Accumulation—Neonatal cardiac myocytes
were prepared and treated as described above and were washed three
times with serum-free and NaHCO3-free Dulbecco’s modified Eagle’s
medium supplemented with 20 mM HEPES, pH 7.4 (DMEH). Cells were
equilibrated for 30 min and then assayed for cAMP accumulation by
incubation with drugs of interest in the presence of 0.2 mM isobutylm-
ethylxanthine for 10 min. When antagonists were used, these agents
were preequilibrated with cells for 10 min before addition of agonists.
Assay medium was aspirated and 250 l of ice-cold trichloroacetic acid
(7.5% w/v) was immediately added to each well to terminate reactions.
TCA extracts were assayed for cAMP content by radioimmunoassay.
Membrane Fractionation—Neonatal rat cardiac myocytes were frac-
tionated using a detergent-free method adapted from Song et al. (21).
Approximately 30 million cells were washed twice in ice-cold PBS and
scraped off the plates in a total of 2 ml of 500 mM sodium carbonate, pH
11. Cells were homogenized with a tissue grinder with three 10-s bursts
and then a sonicator with three 20-s bursts. The homogenate was
brought to 45% sucrose by addition of an equal volume of 90% sucrose
in 25 mM MES, 150 mM NaCl, pH 6.5 (MBS) and loaded in an ultra-
centrifuge tube. A discontinuous sucrose gradient was layered on top of
the sample by placing 4 ml of 35% sucrose prepared in MBS with 250
mM sodium carbonate then 4 ml of 5% sucrose (also in MBS/Na2CO3).
The gradient was centrifuged at 39,000 rpm on a SW41Ti rotor (Beck-
man Instruments) for 16–20 h at 4 °C. The upper light scattering band
at the 5–35% sucrose interface was collected as the caveolin-rich frac-
tion and the lower band (45% sucrose layer) was collected as the non-
caveolin fraction. In some studies, cell were exposed to isoproterenol
(Iso) (1 M) for 10 min before being washed in cold PBS and scraped.
Immunoprecipitation—Immunoprecipitations were performed using
a protein A-agarose method. Briefly, 10-cm plates of neonatal rat cardiac
myocytes were washed twice with cold PBS, scraped in 1 ml of lysis buffer
(50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Igepal CA-630, plus mam-
malian protease inhibitor mixture) and homogenized on ice with 10
strokes in a Dounce homogenizer. Samples were precleared with protein
A-agarose (Roche Molecular Biochemicals) then incubated with primary
antibody for 1–3 h on a rocking platform at 4 °C. Antibody conjugates
were precipitated by incubating with protein A-agarose overnight on a
rocking platform at 4 °C and centrifuging at 13,000 g for 5 min. Protein
A-agarose pellets were then washed once in lysis buffer followed by
washes in wash buffer 2 (50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 0.2%
Igepal CA-630) then wash buffer 3 (10 mM Tris-HCl, pH 7.5, 0.2% Igepal
CA-630). Pellets were suspended in sample buffer containing 20% -mer-
captoethanol and heated at 70 °C for 10 min. Proteins in the immunopre-
cipitates were analyzed by immunoblot analysis.
Immunoblot Analysis—Proteins in individual fractions, whole cell
lysates, or immunoprecipitations were separated by SDS-polyacryl-
amide gel electrophoresis using 10% polyacrylamide precast gels (In-
vitrogen) and transferred to a polyvinylidene difluoride membrane by
electroblotting. In some experiments, protein from samples were pre-
cipitated with trichloroacetic acid before electrophoresis by incubating
with 8% trichloroacetic acid for 30 min on ice, then centrifuging at
3000  g for 15 min. Trichloroacetic acid was aspirated, and pellets
were washed with ethyl ether and dissolved in 4 sample buffer for
SDS-polyacrylamide gel electrophoresis. Membranes were blocked in 20
mM PBS with 3% nonfat dry milk and incubated with primary antibody
overnight at 4 °C. Bound primary antibodies were visualized using
appropriate secondary antibody with conjugated horseradish peroxi-
dase (Santa Cruz Biotechnology) and ECL reagent (Amersham Phar-
macia Biotech). All bands shown migrated at the appropriate size, as
determined by comparison to molecular weight standards (Santa Cruz
Biotechnology). The amount of protein per fraction was determined
using a dye-binding protein assay (Bio-Rad).
RESULTS
Coupling of Endogenous GPCRs to Activation of AC6—Pre-
vious work demonstrates that overexpression of AC6 using an
adenovirus expression system in neonatal rat cardiac myocytes
selectively enhances AR responses compared with several
GPCR that are less efficaciously coupled to Gs and the stimu-
lation of cAMP accumulation (13). To rule out the possibility
that factors requiring the intact cell (e.g., intracellular Ca2,
cytoskeletal proteins, etc.) might contribute to this selective
effect, we assayed AC activity in membranes from neonatal rat
cardiac myocytes. Membranes from control cells or from cells
overexpressing AC6 were assayed using maximal concentra-
tions of Iso (1 M), forskolin (10 M), or PGE2 (10 M). Iso and
forskolin responses were substantially greater in membranes
from AC6-overexpressing cells (Fig. 1A). In contrast, PGE2 (10
M) response, which stimulated AC activity 2.0-fold over basal
levels, was not different in membranes from control or AC6-
overexpressing cells. Therefore, AC6 overexpression selectively
enhances AR-mediated activation of AC activity but not re-
sponse to PGE2.
Coupling Efficiency of AR Subtypes to Activation of AC6—
AR-mediated responses in cardiac myocytes derive from acti-
vation of two different receptors, 1AR and 2AR. We thus
designed experiments to determine the effects of AC6 overex-
pression on responses to the two subtypes of AR (and by
inference, receptor coupling to AC6) by using subtype-selective
antagonists and measuring responses to various concentration
of Iso. Response to Iso yielded an EC50 of 74  1.3 nM and a
maximum of 56  4 pmol of cAMP/mg protein in control cells
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and an EC50 of 110  1.3 nM and a maximum of 181  15 pmol
of cAMP in cells overexpressing AC6 (Fig. 2A and Table I),
consistent with previous studies that increasing expression of
AC6 enhances maximal response without decreasing EC50 (13,
20). However, the impact of AC overexpression was different
between 1AR and 2AR: the maximal response to Iso in the
presence of ICI-118,551 (1AR preferential activation) was en-
hanced 3.7-fold in AC6-overexpressing cells as compared with
control (Fig. 2B). In contrast, the maximal response to Iso in
the presence of CGP-20712A (2AR preferential activation) was
enhanced only 1.6-fold (Fig. 2C). Consistent with their known
actions as competitive antagonists, both ICI-118,551 and CGP-
20712A increased EC50 values for Iso in control and AC6-
overexpressing cells (Table I). Therefore, the data show that
AC6 overexpression enhances 1AR-mediated response more
than 2AR-mediated response, and for both receptors maximal
response was enhanced.
Recent reports indicate that 2AR may couple to both Gs and
Gi (7, 22). To investigate whether coupling of this receptor to Gi
might limit its efficacy in stimulating AC, we measured cAMP
responses to a maximal concentration of Iso in the absence or
presence of either ICI-118,551 (0.1 M) or CGP-20712A (0.1 M)
in cells treated with pertussis toxin (100 ng/ml for 18 h). Per-
tussis toxin treatment had no effect on the level of enhance-
ment by AC6 overexpression to Iso (6.0-fold, Fig. 3) or on 1AR
selective response (i.e. Iso  ICI 118,551, 4.0-fold, data not
shown). However in PTX-treated cells, AC6 overexpression had
a somewhat greater effect on the 2AR-selective response (Iso
 CGP-20712A) than in untreated cells (5.2-fold). This effect
did not reach levels of statistical significance (p  0.077 by
paired Student’s t test) and did not raise the response to levels
attained by 1AR activation. Because neither basal levels of
cAMP nor overall response to Iso were enhanced by treatment
of cells with pertussis toxin, Gi would not appear to exert a
substantial role on cardiomyocyte cAMP generation in re-
sponse to AR activation.
Effect of Increased Expression or Blocked Desensitization on
2AR Coupling to AC6—Because the total AR population in
cardiac myocytes is comprised of 75% 1AR and 25% 2AR
(3), we sought to determine whether the lack of effect of AC6
overexpression on 2AR responses might be attributable to
lower expression of this receptor subtype. We used an adeno-
virus to express an epitope-tagged 2AR in cardiomyocytes
such that the resultant level of 2AR expression was 218-fold
higher than endogenous levels (data not shown). Measuring
cAMP production under conditions that preferentially activate
FIG. 1. AR-mediated adenylyl cyclase activity is selectively
enhanced by AC6 overexpression relative to PGE2 response in
cardiac myocyte membranes and caveolin-3 immunoprecipi-
tates. A, adenylyl cyclase activity in membranes from myocytes ex-
pressing either lacZ (open bars) or AC6 (closed bars). Membranes were
prepared from cultured neonatal rat cardiomyocytes as described under
“Experimental Procedures.” Denotes significantly different from con-
trol: *, p  0.05 and **, p  0.01 by paired Student’s t test. B, adenylyl
cyclase activity in caveolin-3 immunoprecipitates and the IP superna-
tants from cardiomyocytes-overexpressing AC6 (as described under
“Experimental Procedures”). Data are expressed as the mean  S.E. of
3–5 experiments. Denotes significantly different from basal: *, p  0.05
and **, p  0.01 by paired Student’s t test.
FIG. 2. Cardiac myocyte 1AR-mediated increase in cAMP ac-
cumulation is more prominently enhanced by overexpression of
AC6 as compared with 2AR response. cAMP accumulation in re-
sponse to various concentrations of Iso in intact myocytes expressing
either LacZ (squares) or AC6 (circles) in the absence (A) or presence of
either 0.1 M ICI-118,551, a 2-adrenergic selective antagonist (B), or
0.1 M CGP 207124, a 1-adrenergic-selective antagonist (C). Data are
expressed as the mean  S.E. of 4–5 experiments. Observed Ki of
CGP-20712A was 10 nM in LacZ and AC6 cells; observed Ki of ICI-
118,551 was 13 nM in LacZ and AC6 cells (Kd for CGP-20712A at 1AR
is 5 nM and Kd for ICI 118,551 at 2AR is 3.1 nM).
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2AR in 2AR-overexpressing cells, isoproterenol showed a sev-
eralfold shift to the left (i.e. increase in potency) and increase in
maximal response as compared with control cells (Fig. 4A and
Table I). Overexpressing AC6 in addition to 2AR resulted in a
maximal response that was much greater as compared with
cells overexpressing only 2AR. Therefore, overexpression of
2AR enhances its ability to couple to cardiomyocyte AC6 and
to stimulate cAMP formation via AC6.
It has been recently reported that 2AR, but not 1AR, trans-
locate out of caveolin-rich membrane fractions from neonatal
rat cardiac myocytes upon agonist stimulation (10). We hypoth-
esized that this translocation might be associated with ARK
(GRK2)-mediated desensitization of 2AR and thereby contrib-
ute to the lower ability of this receptor to couple to the stimu-
lation of AC6. To test this idea, we used an adenovirus to
express the C-terminal peptide of ARK (ARKct), which
blocks activation of endogenous ARK by sequestering G
subunits (23), thereby blunting desensitization of AR (and
other GPCRs) and increasing AR-mediated signaling (24). We
found that activation of 2AR in cardiomyocytes engineered to
express ARKct yielded about a 12-fold decrease in EC50 and a
1.5-fold increase in maximal cAMP as compared with control
(Fig. 4B and Table I). In this setting of increased functional
2AR, overexpression of AC6 increased the maximal response
to Iso 3.5-fold higher than in cells that only expressed ARKct.
These data imply that blockade of AR desensitization facili-
tates greater coupling of 2AR to AC6. In contrast, ARKct
expression was not able to enhance coupling of EP receptors to
overexpressed AC6, implying that the effect of ARKct was
specific to AR receptors, and not to Gs or AC activation (Fig.
4C). ARKct also did not enhance forskolin-stimulated cAMP
formation in either control of AC6-overexpressing cardiomyo-
cytes (Fig. 4C).
Determination of Receptor and AC6 Co-localization—Immu-
noblot analysis of caveolin-rich membrane fractions isolated
from cardiomyocytes using a detergent-free method has indi-
cated that native AC5/6 is predominantly expressed in caveo-
lin-rich (cav) fractions (10, 13). Overexpression of AC6 substan-
tially increases AC5/6 immunoreactivity in this same fraction
(Fig. 5A and Ref. 13). In addition, native 1AR and adenovirally
expressed FLAG-2AR were predominantly (but not exclu-
sively) detected in cav fractions while EP2 receptor immunore-
activity was detectable only in non-cav fractions (Fig. 5A).
These data provide an explanation for the pattern of receptor
coupling to overexpressed AC6 (Fig. 1A): the absence of an
effect on EP2 receptor responses following AC6 overexpression
correlates with the lack of co-localization of this receptor and
AC6.
As an alternative approach, we performed immunoprecipita-
tions and analyzed the proteins that co-precipitated using im-
munoblotting and by measuring AC activity. AC activity meas-
ured in caveolin-3 immunoprecipitates (designated as IP) was
stimulated by forskolin and isoproterenol, but not by PGE2
(Fig. 1B, IP). In contrast, AC activity in the IP supernatant (all
cellular material not bound by caveolin-3 antibody) could be
stimulated by PGE2. Basal AC activity was 3.2-fold higher in
the caveolin-3 IP than in the IP supernatants. Immunoblot
analysis of the caveolin-3 IP demonstrated the presence of
1AR, AC5/6, and expressed FLAG-2AR (Fig. 5B) but not
EP2R (data not shown). Conversely, caveolin-3 immunoreactiv-
ity was detected in both 1AR and AC5/6 IP from native cells as
well as in the FLAG IP from cells expressing FLAG-2AR.
Further IP studies indicated that 1AR and AC5/6 co-immuno-
precipitated but that 2AR did not immunoprecipitate with
either 1AR or AC5/6 (data not shown). Therefore, 1AR and
AC5/6 and caveolin-3, and to a lesser extent 2AR, form sig-
naling complexes that exclude EP2R.
Rybin et al. (10) reported that agonist exposure causes a
translocation of 2AR, but not 1AR, out of caveolin-rich frac-
tions from cardiomyocytes (9). We exposed cells expressing
FLAG-2AR to Iso (1 M) for 10 min before performing immu-
noprecipitations and found that FLAG-2AR immunoreactivity
was reduced in caveolin-3 IP. When these studies were re-
peated in cardiomyocytes also expressing ARKct, overall
FLAG-AR immunoreactivity in caveolin-3 IP was increased
and Iso exposure no longer diminished FLAG-2AR co-precip-
itation with caveolin-3 (Fig. 5B). Neither Iso stimulation nor
ARKct expression altered the co-precipitation of 1AR or
AC5/6. Therefore, whether assessed by either cell fractionation
TABLE I
Effect of AC and/or receptor expression on the potency and efficacy of isoproterenol in stimulating cAMP production
EC50 and maximum values (pmol of cAMP/mg of protein) of Iso stimulation of cAMP accumulation in the presence of 1AR- and/or 2AR-selective
antagonists CGP-20712A (0.1 M) and ICI-118,551 (0.1 M) from control and AC6-overexpressing cardiomyocytes. Values are also shown in
cardiomyocytes expressing either 2AR or ARKct in addition to LacZ or AC6.
LacZ (control) AC6
EC50 Maximum EC50 Maximum
nM pmol nM pmol
Iso 74.0 56.0 110 181
Iso  CGP-20712A 650 27.7 540 43.5
Iso  ICI-118,551 780 41.6 1000 156
Iso  CGP-20712A and ICI-118,551 16380 11.5 12210 26.2
2AR overexpression Iso  CGP-20712A 170 80.3 340 270
ARKct expression Iso  CGP-20712A 56 42.4 68 149
FIG. 3. Coupling of neonatal cardiac myocyte 2AR to AC6 to
pertussis toxin-sensitive G proteins. cAMP accumulation was
measured in response to Iso alone or in the presence of a 2AR subtype-
specific antagonist in LacZ- (open bars) or AC6-overexpressing cells
(solid bars) or cells treated with pertussis toxin (100 ng/ml for 18 h;
LacZ, hatched bars; AC6, cross-hatched bars). Data are expressed as the
mean  S.E. of three experiments. Pertussis toxin treatment did not
significantly increase the 2AR-selective response in AC6 overexpress-
ing cells (p  0.077 by paired Student’s t test).
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(9) or caveolin-3 immunoprecipitation (Fig. 5B), 2AR translo-
cate out of caveolae upon agonist exposure. This translocation
appears dependent upon GRK and presumably occurs as req-
uisite for 2AR internalization via clathrin-coated pits (25, 26).
We also show that ARKct expression blocks this 2AR trans-
location and enhances 2AR coupling to AC (Fig. 4), the latter
effect likely resulting from an increased number of functional
receptors in the compartment enriched in AC6.
DISCUSSION
It is well established that cells achieve their differentiated
state and fulfill specialized cellular functions by expressing
only a certain subset of genes. For example, the complement of
cell-surface receptors that a given cell expresses determines
the extracellular signals to which that cell will respond. How-
ever, because receptors may share common signal transduction
mechanisms, spatial targeting to particular domains of recep-
tors with similar signaling characteristics provides a means of
achieving specificity in signaling. Such observations contradict
the classical paradigm that receptors and other integral mem-
brane proteins are randomly distributed in the plasma mem-
brane. The present work demonstrates that caveolin-rich do-
mains, plasma membrane microdomains that are enriched in
many signaling molecules, can co-localize receptors and effec-
tors to couple only certain receptors to a given effector. Data
FIG. 4. Increased expression of 2AR or inhibition of GRK in
cardiac myocytes uncovers an enhancement of 2AR responses
by AC6 overexpression. cAMP accumulation in response to various
concentrations of Iso in the presence of a 1AR antagonist (0.1 M CGP
207124) in intact myocytes expressing either LacZ (squares) or AC6
(circles). A, cells overexpressing 2AR (closed squares) in addition to
either LacZ or AC6. Responses from myocytes with LacZ and AC6
overexpression alone are shown for comparison (open symbols, data
from Fig. 2). B, cells in which GRK activation was blocked by expressing
the carboxyl-terminal peptide of ARK (ARKct, closed squares). Re-
sponses from LacZ and AC6 overexpression alone are shown for com-
parison (open symbols, data from Fig. 2). C, cAMP accumulation re-
sponses to forskolin, Iso, and PGE2 in control cells (open bars) or cells
expressing ARKct (hatched bars), AC6 (closed bars), or ARKct and
AC6 (cross-hatched bars). Data are expressed as the mean S.E. of 4–5
experiments. Denotes significantly different from control: *, p  0.05
and **, p  0.01 by paired Student’s t test.
FIG. 5. ARKct expression blocks agonist-induced transloca-
tion of 2AR out of cardiac myocyte caveolin-rich fractions. A,
expression of caveolin-3, AC5/6, 1AR, FLAG-2AR, and EP2R was
assessed by immunoblot analysis of caveolin-rich and caveolin-poor
membrane fractions and whole cell lysates from cardiomyocytes. Frac-
tions from cells overexpressing AC6 (AdV-AC6) were also analyzed for
AC5/6 immunoreactivity. B, caveolin-3 immunoprecipitates (IPs) from
control cells or cells expressing ARKct that were exposed to either
vehicle or Iso (1 M for 10 min, Iso) were analyzed by immunoblotting.
Immunoreactivity for 2AR was lost in caveolin-3 immunoprecipitates
from Iso-treated cells unless ARKct was expressed. 1AR and AC5/6
immunoreactivity was unchanged by these treatments. Images are
representative of at least three experiments.
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from previous work by our laboratory and others suggest that
such caveolin-rich domains represent morphologic caveolae
(13, 27). Thus spatial, as well as temporal, regulation of sig-
naling can be a critical determinant for individualizing cellular
response to extracellular hormones and neurotransmitters
(18).
Consistent with previous findings, we find that cardiomyo-
cytes compartmentalize a significant proportion of AR-AC
signaling in buoyant, caveolin-rich membranes (10, 11, 13). We
show that another type of receptor capable of stimulating AC,
the EP2 receptor, is excluded from caveolin-rich fractions and is
unable to couple to overexpressed AC6. Therefore, localization
in this subcellular compartment is a determinant for efficacy of
GPCR coupling to an effector molecule. 1AR, expressed at
larger numbers and apparently more permanently residing in
caveolae, couple with high efficacy to AC6. 2AR, expressed at
lower levels as compared with 1AR, also reside in caveolae but
translocate out of this microdomain upon agonist activation
(10). This translocation occurs within the time frame of cAMP
accumulation assays and appears to contribute to the de-
creased ability of 2AR to maximally stimulate AC6. These
data for 1AR, 2AR and EP2R provide direct demonstration of
the functional significance of co-localization of GPCR signaling
molecules in caveolin-rich domains and do so using endogenous
receptors in primary cultures of a physiologically important cell
type.
Cardiomyocyte caveolae may serve as specialized regions
that integrate multiple signaling pathways with other signal-
ing events and concentrate critical signaling proteins involved
in creating temporal and spatial patterns of cell regulation. For
example, caveolae have been implicated as sites of Ca2 sparks
(28) in cardiomyocytes and the location of capacitive Ca2 entry
in other cells (19). If Ca2 entry is localized in caveolae, expres-
sion of AC6 (a Ca2-inhibitable isoform) in this same microdo-
main should result in cAMP levels that are highly sensitive to
Ca2 entry from outside the cell. In fact, this is the case in C6
glioma cells, which express AC6 and require intact caveolae for
capacitive Ca2 entry to inhibit AC activity (19). Such co-
localization in cardiomyocytes might contribute to the changes
in cAMP levels observed in heart during the cardiac cycle (29)
and might contribute to regulation of cAMP levels by nitric
oxide (30). Changing the localization of AC6 expression would
be predicted to result in a different pattern of regulation of
cAMP levels. Consistent with this hypothesis, AC activity is
increased when cardiomyocyte caveolae are disrupted with cy-
clodextrin, a moiety that removes cholesterol from the plasma
membrane and presumably dissociates sites of Ca2 entry from
endogenous AC (10).
A further prediction that would derive from our findings is
that overexpression of different isoforms of AC would result in
different patterns of regulation and have different physiologi-
cal consequences. Indeed, overexpression of AC isoforms other
that AC6 has been reported to produce quite different effects on
cellular and cardiac physiology. Overexpression of AC8, which
is poorly activated by GPCRs, leads to a Ca2-dependent reg-
ulation of the enzyme without enhancement of GPCR re-
sponses (31). Transgenic overexpression of AC5 results in in-
creases in basal AC activity and little enhancement, on a
percent basis, of AR-mediated responses (32). These data
contrast with data presented here and with data from trans-
genic overexpression of AC6 (33). AC5 and AC6 are similar in
their regulation by Ca2 and PKA, but AC5 is stimulated while
AC6 is inhibited by PKC. This difference in regulation may be
quite relevant given that PKC translocates to caveolae upon
activation (27). However, most previous work has not involved
assessment of co-localization of AC and receptors that regulate
its activity. The present work illustrates the importance of
understanding the subcellular localization of both AC and re-
ceptor expression.
There are certain caveats of the present findings. One is that
the co-localization of proteins relies upon a biochemical isola-
tion of buoyant membrane fractions. These fractions may not
necessarily be pure morphologic caveolae. Although our efforts
to perform electron microscopic studies confirm a caveolae-like
structure (13), such fractions may also represent different mi-
crodomains of the cell, such as lipid rafts (34). While the im-
munoprecipitation studies in this report were designed to mit-
igate this shortcoming, definitive proof of co-localization of
receptors and AC will likely require additional approaches,
such as morphologic studies at the electron microscopic level.
Unfortunately, antibodies presently available are of limited
usefulness in these types of studies.2 Also, it is conceivable that
localization patterns of components in the neonatal cardiomyo-
cyte may not be identical with those in adult cardiomyocytes.
Direct studies to test this will need to be undertaken. In addi-
tion, it is important to consider that ARKct blocks GRK acti-
vation by sequestering G subunits (23). Thus, any changes in
cAMP formation resulting from ARKct expression may be
attributable, in part, to the termination of signaling by G and
mechanisms other than blockade of desensitization.
In conclusion, these studies of GPCR-AC signal transduction
in cardiomyocytes demonstrate that compartmentation of re-
ceptors and AC isoforms can determine the efficacy of receptor
coupling in that different GPCR show different patterns of
cAMP generation, which correlate with co-localization in caveo-
lin-rich domains. The co-localization of GPCR-signaling com-
ponents in such microdomains has important implications for
the regulation of cellular responses to extracellular hormones
and neurotransmitters. Most previous work that has examined
mechanisms of signal transduction has involved isolation, pu-
rification, cloning, and reconstitution of purified components.
The studies here emphasize the potentially critical role of spa-
tial organization, at a subcellular level, of key signaling mole-
cules in defining the ability of cells to respond to extracellular
stimuli. It will be of interest to learn how such spatial organi-
zational changes as a consequence of development, physiologic
state, and in disease settings. The recognition of signaling
microdomains in caveolin-rich regions of cardiomyocytes and
other cells may provide a unifying hypothesis to help account
for the rapidity, high fidelity, and specificity of GPCR-mediated
signal transduction.
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